Drugs / 3F8
3F8
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00492167 | Sep 2005 → Mar 2022 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00450307 | Jun 2005 → Apr 2013 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00037011 | Nov 2001 → Jan 2005 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT01183429 | Aug 2010 → Sep 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01183897 | Aug 2010 → Sep 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01183884 | Aug 2010 → Nov 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01183416 | Aug 2010 → Oct 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00445965 | Jan 2006 → Feb 2023 | central nervous system neoplasm, cutaneous melanoma, lung cancer, metastatic malignant neoplasm +6 | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00089258 | Jul 2004 → Nov 2006 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00072358 | Jul 2003 → Jan 2021 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00040872 | Jun 2000 → Jan 2007 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00004110 | Aug 1999 → Sep 2004 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002634 | Feb 1995 → Sep 2004 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002560 | Feb 1994 → Apr 2005 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002458 | Nov 1987 → Sep 2001 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02100930 | Mar 2014 → Mar 2019 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00877110 Background | Apr 2009 → Jan 2019 | bone marrow disorder, neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3F8 | “Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.” NCT00445965 ↗ |
| Known as | HM3F8 | “Heat-modified 3F8 (HM3F8) lacks effector functions” PMID 21343563 ↗ Feb 2011 |
| Known as | MOAB 3F8 | “Patients receive monoclonal antibody 3F8 (MOAB 3F8) IV over 1.5 hours once daily on days 1-10 and oral etoposide once daily on days 29-49.” NCT00004110 ↗4“Treatment with monoclonal antibody 3F8 (MOAB 3F8) starts after completion of course 3 of intensive induction chemotherapy” NCT00040872 ↗ “Antiganglioside GD2-specific Monoclonal Antibody 3F8, MOAB 3F8.” NCT00002458 ↗ “iodine I 131 labeled monoclonal antibody 3F8 (MOAB 3F8)” NCT00002634 ↗ “monoclonal antibody 3F8 (MOAB 3F8)” NCT00037011 ↗ |
| Action | Deplete | “monoclonal antibody 3F8, can locate tumor cells and either kill them” NCT00072358 ↗ |
| Modality | Monoclonal antibody | “Antiganglioside GD2-specific Monoclonal Antibody 3F8” NCT00002458 ↗ |
| Route | Intravenous | “Patients receive monoclonal antibody 3F8 IV over 1.5 hours” NCT00002560 ↗ |